Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VHL | P40337 | 20/20 | 0.35 |
| ▸ | SMARCA2 | P51531 | 2/20 | 0.35 |
| ▸ | SMARCA4 | P51532 | 2/20 | 0.35 |
| ▸ | ELOC | Q15369 | 10/20 | 0.35 |
| ▸ | ELOB | Q15370 | 10/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26653886 | 0.92 | VHL (0.43) | VHLSMARCA2SMARCA4ELOCELOB | |
| SCHEMBL26653883 | 0.92 | VHL (0.43) | VHLSMARCA2SMARCA4ELOCELOB | |
| SCHEMBL30658010 | 0.88 | — | — | |
| SCHEMBL30658032 | 0.85 | VHL (0.56) | VHLSMARCA2SMARCA4ELOCELOB | |
| SCHEMBL31589099 | 0.85 | VHL (0.56) | VHLSMARCA2SMARCA4ELOCELOB | |
| SCHEMBL30658033 | 0.85 | MAPT (0.31) | — | |
| SCHEMBL31582569 | 0.81 | VHL (0.40) | VHLSMARCA2SMARCA4ELOCELOB | |
| SCHEMBL26804410 | 0.78 | PBRM1 (0.33) | VHLSMARCA2SMARCA4 | |
| SCHEMBL26804537 | 0.77 | VHL (0.58) | VHLSMARCA2SMARCA4 | |
| SCHEMBL26804406 | 0.75 | MAPT (0.32) | VHLSMARCA2SMARCA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250302832-A1 | PYRAZINE DERIVATIVES AND USES THEREOF | FOGHORN THERAPEUTICS INC (US) | 2025-10-02 | — | — | US | disclosed |
| CN-120035593-A | Pyrazine derivatives and uses thereof | 福宏治疗公司 | 2025-05-23 | — | — | CN | disclosed |
| EP-4522279-A1 | PYRAZINE DERIVATIVES AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| WO-2023220134-A1 | PYRAZINE DERIVATIVES AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2023-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250302832-A1 | PYRAZINE DERIVATIVES AND USES THEREOF | BRCA1, VHL, SF3B5 | VHL 2/4885SMARCA2 77/4885SMARCA4 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.